Biobot Analytics, a leader in wastewater intelligence, announced a new funding round led by Valor Equity Partners. Along with Valor, Biobot is also welcoming new investor Atreides Management, as well as participation from existing investors, including Hyperplane.
The funding reflects strong ongoing support for Biobot’s mission to build a wastewater intelligence platform for healthcare and national security applications.
Launched at the Massachusetts Institute of Technology, Biobot Analytics pioneered wastewater-based epidemiology in cities. From tracking COVID-19 trends across hundreds of communities to detecting opioid use and other health indicators, Biobot’s technology empowers governments and organizations with critical data.
How the funding will be used: The funding will support the company’s expanding suite of wastewater intelligence offerings, enabling continued innovation in advanced analytics, product development, and partnerships across government and commercial sectors.
New board members: As part of this round, Biobot is pleased to welcome new board members:
— Vivek Pattipati, Partner at Valor Equity Partners, joins as Board Director
— Andrew Perlman, Partner at Atreides Management, joins as Board Director
— Vivjan Myrto, Managing Partner at Hyperplane, joins as Board Observer
And they join Biobot’s cofounders and existing Board Directors, Dr. Mariana Matus and Newsha Ghaeli, in guiding the company’s long-term strategy.
KEY QUOTES:
“We are proud to be backed by some of the most forward-thinking investors in the tech industry. Their support and insight will be instrumental as we build a new category of health intelligence—using wastewater data to create a safer, healthier, and more resilient society.”
Dr. Mariana Matus, CEO of Biobot Analytics
“Biobot is a category-defining company with a bold vision for the future of healthcare and biosecurity. We’re excited to support the talented team at Biobot as they bring innovative new products to market.”
Vivek Pattipati, Partner at Valor Equity Partners
